Premium
Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma? A DEGOG* Study
Author(s) -
Saygili Ugur,
Guclu Serkan,
Uslu Turhan,
Erten Oktay,
Ture Sevgi,
Demir Namik
Publication year - 2002
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.10124
Subject(s) - medicine , stage (stratigraphy) , lymphadenectomy , oncology , ovarian carcinoma , gynecology , ovarian cancer , cancer , paleontology , biology
Background and Objectives The aim of this study was to investigate whether systematic lymphadenectomy is necessary in suboptimally cytoreduced patients with stage III ovarian carcinoma. Methods Prognostic significance and the effect on survival of systematic pelvic and para‐aortic lymphadenectomy were investigated retrospectively in 61 suboptimally debulked patients with stage III ovarian carcinoma. All patients received platinum‐based chemotherapy after surgery; 51 patients had been followed for ≥1 year, or until death. Survival curves were calculated according to the Kaplan‐Meier method and were evaluated by log‐rank test. Results Most patients had stage IIIC disease (60.7%), poorly differentiated tumor (45.9%), and serous histological type (59%). Systematic pelvic and para‐aortic lymphadenectomy was performed in 29 patients (47.5%). Lymph node metastases were found in 17 (58.6%) patients; the median number of metastatic nodes was 7 (5–10). Lymph node metastasis was significantly higher in patients with residual disease of >2 cm ( P < 0.05). Both univariate and multivariate analyses showed that systematic pelvic and para‐aortic lymphadenectomy was not a significant prognostic factor ( P > 0.05). In lymph node‐dissected patients, survival was significantly longer in patients with minimal residual tumor than in those with residual tumor size >2 cm ( P = 0.005). Conclusions Lymphadenectomy seems not to have an evident prognostic value and a benefit on survival in suboptimally debulked patients with stage III ovarian carcinoma. J. Surg. Oncol. 2002;81:132–137. © 2002 Wiley‐Liss, Inc.